Hypertension in women: The role of progesterone and aldosterone

Climacteric

Volumn 13, Issue 4, 2010, Pages 307-313

  Boschitsch, E ^a   Mayerhofer, S ^b   Magometschnigg, D ^c  

^a KLIMAX Menopause Clinic   (Austria)

^b Cytro Medical and Clinical Project Management   (Austria)

^c Institute for Hypertension   (Austria)

Author keywords

Blood pressure; Drospirenone; Gender; Hypertension; Menopause; Progesterone; Reninangiotensinaldosterone System; Salt sensitivity

Indexed keywords

ALDOSTERONE; CHLORMADINONE ACETATE; CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; DROSPIRENONE; ETHINYLESTRADIOL; ETYNODIOL DIACETATE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PROGESTERONE; SPIRONOLACTONE; ANDROSTANE DERIVATIVE; ESTRADIOL; ESTROGEN; MINERALOCORTICOID ANTAGONIST; PROGESTERONE DERIVATIVE;

BLOOD PRESSURE; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MENOPAUSE; OVARIECTOMY; PREGNANCY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; AGED; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; NATRIURESIS; PHYSIOLOGY; RISK FACTOR; SEXUAL DEVELOPMENT; SODIUM RESTRICTION;

AGED; ALDOSTERONE; ANDROSTENES; ANIMALS; CARDIOVASCULAR DISEASES; DIET, SODIUM-RESTRICTED; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NATRIURESIS; PROGESTERONE; PROGESTERONE CONGENERS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SEX CHARACTERISTICS;

EID: 77953575557     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697131003624649     Document Type: Review

References (57)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European Countries, Canada, and the United States. JAMA 2003; 289:2363-2369
2. Dasgupta K, O'Loughlin J, Chen S, et al. Emergence of sex difference in prevalence of high systolic blood pressure: analysis of a longitudinal adolescent cohort. Circulation 2006;114:2663-2670
3. Zanchetti A, Facchetti R, Cesana GC, Modena MG, Pirelli A, Sega R, on behalf of the SIMONA participants. Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study. J Hypertens 2005;23:2269-2276
4. Reckelhoff JF, Zhang H, Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats. Role of the renin-angiotensin system. Hypertension 2000;35:480-483
5. Harrison-Bernhard LM, Schulman IH, Raij L. Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity. Hypertension 2003;42: 1157-1163
6. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913
7. Vasan RS, Larson MG, Leip EP, et al. Impact of highnormal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-1297
8. Guidelines Committee. 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007;25: 1105-1187
9. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension, an age-old debate. Hypertension 2008;51: 952-959
10. Landau RL, Bergenstal DM, Lugibihl K, Kascht ME. The metabolic effects of progesterone in man. J Clin Endocrinol Metab 1955;15:1194-1215
11. Derkx FH, Steunkel C, Schalekamp MP, Visser W, Huisveld IH, Schalekamp MA. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J Clin Endocrinol Metab 1986;63:1008-1015
12. Oelkers W. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996;61:166-171
13. Crane MG, Harris JJ. Effects of estrogens and gestagens on the renin-aldosterone system. In Fregly MJ, Fregly MS, eds. Oral Contraceptives and High Blood Pressure. Gainesville, Florida: Dolphin Press, 1974
14. Oelkers W, Schöneshöfer M, Blümel A. Effects of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man. J Clin Endocrinol Metab 1974;39:882-890
15. Calhoun DA, Oparil S. High blood pressure in women. Int J Fertil 1997;42:198-205
16. Cifkova R, Pitha J, Lejskova M, Lanska V, Zecova S. Blood pressure around the menopause: a population study. J Hypertension 2008;26:1976-1982
17. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-1057
18. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-221
19. Rosano GM, Fini M. Comparative cardiovascular effects of different progestins in menopause. Int J Fertil Womens Med 2001;46:248-256
20. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
21. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534
22. Weinberger MH. Pathogenesis of salt sensitivity of blood pressure. Curr Hypertens Rep 2006;8:166-170
23. Pechère-Bertschi A, Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens 2004;17: 994-1001
24. Pechère-Bertschi A, Maillard M, Stadler H, Brunner HR, Burnier M. Renal segmental tubular response during the normal menstrual cycle. Kidney Int 2002; 61:425-431
25. Schulman IH, Aranda P, Raij L, Veronesi M, Aranda FJ, Martin R. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006;47:1168-1174
26. Morimoto A, Uzu T, Fujii T, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1997;350:1734-1737
27. Cubeddu LX, Hoffmann IS, Aponte LM, et al. Role of salt sensitivity, blood pressure, and hyperinsulinemia in determining high upper normal levels of urinary albumin excretion in a healthy adult population. Am J Hypertens 2003;16:343-349
28. Schulman IH, Raij L. Salt sensitivity and hypertension after menopause: role of nitric oxide and angiotensin II. Am J Nephrol 2006;26:170-180 (Pubitemid 43882402)
29. Szmuilowicz ED, Adler GK, Williams JS, et al. Relationship between aldosterone and progesterone in the human menstrual cycle. J Clin Endocrin Metab 2006;91:3981-3987
30. Pechère-Bertschi A, Burnier M. Gonadal steroids, saltsensitivity and renal function. Curr Opin Nephrol Hypertens 2007;16:16-21
31. Connell JM, Davis E. The new biology of aldosterone. J Endocrinol 2005;186:1-20
32. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 1983;80:6056-6060
33. Pearce P, Funder JW. High affinity aldosterone binding sites (type I receptors) in rat heart. Clin Exp Pharmacol Physiol 1987;14:859-866
34. Fujisawa G, Dilley R, Fullerton MJ, Funder JW. Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration. Endocrinology 2001;142:3625-3631
35. Oberleithner H, Riethmüller C, Ludwig T, Hausberg M, Schillers H. Aldosterone remodels human endothelium. Acta Physiol 2006;187:305-312
36. Schlaich MP, Schobel HP Hilgers K, Schmieder RE. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 2000;85:1199-1206
37. Rocha R, Stier CT, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-3878
38. Rocha R, Stier CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001;12:308-314
39. Funder JW. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J 2002;144:S8-11
40. Freel EM, Connell JM. Mechanisms of hypertension: the expanding role of aldosterone. J Am Soc Nephrol 2004; 15:1993-2001
41. Rahmouni K, Correia MLG, Haynes WG, Mark AL. Obesity-associated hypertension. New insights into mechanisms. Hypertension 2005;45:9-14
42. El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 2004;15: 2816-2827
43. Catena C, Lapenna R, Baroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: a follow up study. J Clin Endocrinol Metab 2006;91:3457-3463
44. Caprio M, Zennaro MC, Feve B, Mammi C, Fabbri A, Rosano G. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with the mineralocorticoid receptor. Climacteric 2008;11: 258-264
45. Kagawa CM, Cella JA, Van Arman CG. Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 1957;126:1015-1016
46. Pollow K, Juchem M, Elger W, Jacobi N, Hoffmann G, Möbus V. Dihydrospirorenone (ZK30595): a novel synthetic progestagen - characterization of binding to different receptor proteins. Contraception 1992;46:561-574
47. De Gasparo M, Joss U, Ramjoué HP, et al. Three new epoxy-spirolactone derivatives: characterisation in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-656
48. Elger W, Beier S, Pollow K, Garfield R, Qing Shi S, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 2003;68:891-905
49. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Contraception 1995;51: 99-110
50. Sitruk-Ware R. New progestogens. A review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004;21:865-883
51. Preston RA, Alonso A, Panzitta D, Zhang P, Karara AH. Additive effect of drospirenone/17b-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002;15:816-822
52. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17b-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979-1984
53. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17b-estradiol, in postmenopausal women with hypertension. Hypertension 2006;48:246-253
54. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17b-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005;18:797-804
55. Preston RA, Norris PM, Alonso AB, Ni P, Hanes V, Karara AH. Randomized, placebo-controlled trial of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007;14:1-7
56. Schürmann R, Blode H, Benda N, Cronin M, Küfner A. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. J Clin Pharmacol 2006;46:867-875
57. Svetkey LP. Management of prehypertension. Hypertension 2005;45:1056-1061